If You Invested $1,000 in Repligen (RGEN)
This article analyzes the historical performance of investing $1,000 in Repligen (RGEN) over 1, 5, and 10 years, detailing the total return and Compound Annual Growth Rate (CAGR). It also provides an annual performance comparison of RGEN against the S&P 500 and offers a company overview, including its business focus, products, global operations, and financial reporting. The article concludes by highlighting key themes in Repligen's public communications and its industry classification within the life sciences sector.
Repligen Corporation(NasdaqGS: RGEN) dropped from Russell Midcap Growth Benchmark
Repligen Corporation (NasdaqGS: RGEN) has been removed from the Russell Midcap Growth Benchmark. This news follows a series of recent events for the company, including presentations at healthcare conferences and its Q1 2026 earnings report, where it posted better-than-expected adjusted EPS and revenue. Analysts currently maintain a consensus "BUY" rating on the stock with a target price significantly above its last close.
Price to sales forward of Repligen Corporation – NASDAQ:RGEN
The article provides a financial metric for Repligen Corporation (NASDAQ: RGEN), specifically its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and there were no trades. The content offers a snapshot of a financial data point for the company on TradingView.
Price to earnings forward of Repligen Corporation – NASDAQ:RGEN
This page provides financial information for Repligen Corporation (NASDAQ:RGEN), specifically focusing on its forward Price to Earnings (P/E) ratio. It indicates that the market for RGEN is currently closed with no trades. The content is primarily a data placeholder from TradingView, offering little in terms of actual financial values or analysis at this time.
Price to book forward of Repligen Corporation – BX:RGN
The article displays the "Price to book forward" for Repligen Corporation (RGN) on the BX Swiss exchange. It notes that the market is currently closed with no trades. The content primarily shows financial data available through TradingView, including a historical overview, and highlights that the data is sourced from ICE Data Services and FactSet.
Enterprise value to EBITDA forward of Repligen Corporation – NASDAQ:RGEN
This article displays the enterprise value to EBITDA forward for Repligen Corporation, traded as RGEN on the Nasdaq Stock Market. It presents the period, value, and change information for this financial metric. The content is primarily a data point from TradingView's financial analysis tools.
Enterprise value to revenue forward of Repligen Corporation – BX:RGN
The article focuses on the "Enterprise value to revenue forward" metric for Repligen Corporation, traded on the BX Swiss exchange under the symbol RGN. It presents this financial data point for the company. The content primarily highlights where to find this financial detail within the TradingView platform.
Repligen Corporation Actuals & Estimates (DUS:RGN)
This article provides financial actuals and estimates for Repligen Corporation (DUS:RGN), including income statement, balance sheet, and cash flow data, alongside analyst price targets. It covers frequently asked questions regarding its stock ticker, forecast, historical prices, earnings reports, revenue, net income, dividends, employee count, and EBITDA. The company's next earnings report is expected on August 4, 2026.
Insider Sell: Jason Garland Sells Shares of Repligen Corp (RGEN)
Jason Garland, CFO of a Repligen Corp (RGEN) subsidiary, sold 733 shares of the company on June 25, 2026. This transaction leaves him with 19,359 shares. The stock, trading at $145 with a market cap of $8.292 billion, is considered modestly undervalued with a price-to-GF-Value ratio of 0.82, despite having a high P/E ratio compared to its industry.
Repligen Corporation Actuals & Estimates (NASDAQ:RGEN)
This article provides an overview of Repligen Corporation (NASDAQ: RGEN) stock, including its current price, market capitalization, and historical performance. It details financial actuals and estimates, analyst forecasts for future price targets, and information on earnings reports and revenue. The article also addresses frequently asked questions regarding the stock's volatility, dividends, and employment figures.
Repligen (RGEN) CFO completes 733-share Rule 10b5-1 stock sale
Repligen's CFO, Jason K. Garland, sold 733 shares of the company's common stock at $145 per share in a pre-planned transaction. This sale, totaling $106,285, was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the transaction, Garland directly owns 19,359 shares of Repligen common stock.
Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh Actuals & Estimates (BMFBOVESPA:R2GE34) — TradingView
The article provides an overview of Repligen Corporation (BMFBOVESPA:R2GE34) on TradingView, focusing on its financial actuals and estimates. It highlights features for exploring reported financial data, analyst estimates across various statements, and comparing actual results with projections. The content aims to help users visualize financial trends for investment research.
RGN Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and financial overview for Repligen Corporation (RGN) stock. It includes analysts' price targets, past performance data, earnings reports, revenue figures, and other key financial metrics. The article also addresses frequently asked questions about the company's stock, such as its current price, market capitalization, and employee count.
Form 144 REPLIGEN CORP For: 25 June By Investing.com
This article announces the filing of Form 144 for Repligen Corp (RGEN) on June 25. Form 144 indicates an intent to sell restricted securities. The brief notice provides the company name, the form type, and the date of the filing.
[144] REPLIGEN CORP SEC Filing
This article reports on a Form 144 SEC filing by Repligen Corp (RGEN). The filing indicates a proposed sale of 733 shares of common stock with an aggregate market value of $106,285, acquired through restricted stock vesting on November 18, 2024. The filing was accepted by SEC EDGAR on June 25, 2026, at 01:55 PM.
Repligen Corp (RGEN) Shares Fall 4.1% -- What GF Score of 83 Tells Investors
Repligen Corp (RGEN) shares fell 4.1% on June 22, 2026, dropping to $126.67. Despite this, the stock is considered 28.0% undervalued according to its GF Value™ of $175.89, and holds a strong GF Score™ of 83/100, primarily due to high growth potential. However, recent insider selling of $0.5M and a low momentum rank of 4/10 suggest caution for investors.
Repligen Corporation (RGEN) Stock Analysis: Assessing a 33% Upside Potential in Bioprocessing Innovation
Repligen Corporation (RGEN) is a significant player in the bioprocessing sector within the healthcare industry, with a market capitalization of $7.45 billion. Analysts are optimistic, projecting a 33.39% upside potential from its current trading price of $132.02, supported by strong revenue growth and strategic collaborations. The company's diverse and advanced product offerings, alongside technical indicators suggesting a potentially bullish trend, position it well for continued success in the expanding life sciences and biopharmaceutical industries.
Repligen Stock - Long-term strategy and bioprocessing niche
This article focuses on Repligen (US7607591002), a specialized life-science tools provider, and its long-term strategy in the bioprocessing market. It highlights the company's business model, which centers on supplying technologies for biologic drug manufacturing, positioning it as a "picks-and-shovels" supplier to the growing biologics market. The article also discusses Repligen's growth logic, its approach to scale through organic development and acquisitions, and the risk factors inherent in its business model, such as exposure to biopharma capital spending cycles and competition.
Repligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences Tools
Repligen Corporation (RGEN) saw its stock slide due to a softened enthusiasm for life sciences tools, despite offering bullish Q1 guidance and having no exposure to NIH funding slowdowns. Osterweis Capital Management, which holds RGEN, attributed the sector's concerns to a slowdown in NIH purchasing but remains positive on Repligen's outlook and anticipates improved sentiment in Q2. While Repligen's one-month return was positive, the broader challenges in the life sciences sector impacted its Q1 performance within the fund's portfolio.
Repligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences Tools
Osterweis Capital Management's Q1 2026 investor update highlighted Repligen Corporation (NASDAQ: RGEN), noting its underperformance due to a general softening in enthusiasm for life sciences tools. Despite this, the fund remains positive about Repligen, citing its lack of exposure to NIH funding slowdowns and bullish Q1 guidance. The firm expects sentiment for the sector to improve, leading to a potential reversal of negative momentum for RGEN.
RGEN Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Repligen Corp (RGEN), indicating a "Strong Buy" consensus based on various technical indicators. While overall sentiment is strong buy, the stock is trading below its 200-day moving average. The analysis details momentum indicators, support and resistance levels, and moving average signals to help investors understand its current market position.
Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed breakdown of Repligen Corp's (RGEN) revenue by business segment and geographical region, updated as of April 6. For FY2025, filtration products contributed the largest share of revenue, followed by chromatography products, protein products, and process analytics products. Geographically, North America accounted for the largest portion of revenue, with Europe and APAC/Other regions also making significant contributions.
Repligen Corp (RGEN) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Repligen Corp (RGEN), listing major institutional holders like BlackRock, T. Rowe Price, and Vanguard. It breaks down shareholder types by proportion and provides a historical overview of institutional shareholding data from Q4 2023 to Q1 2026, including changes in shares held. The report also identifies related ETFs that hold RGEN stock.
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Repligen Corp (RGEN), highlighting its current earnings forecast score, average price target of $190.00, and analyst ratings, with most analysts recommending a "Buy." It also includes peer comparisons and answers frequently asked questions regarding revenue expectations, price targets, and past EPS performance.
Repligen Corp (RGEN) Institutional Confidence
Repligen Corp (RGEN) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. This score reflects a 116.89% institutional shareholding proportion, which increased by 3.23% quarter-over-quarter. Lee Ainslie is the largest institutional shareholder, holding 1.58M shares, which represents 2.69% of shares outstanding.
Is Q1 Beat And Reaffirmed 2026 Guidance Altering The Investment Case For Repligen (RGEN)?
Repligen (RGEN) reported better-than-expected Q1 2026 revenue and adjusted EPS, and reaffirmed its full-year 2026 guidance, prompting RBC Capital to resume coverage with an Outperform rating. This performance reinforces the company's focus on profitable growth in the bioprocess market. While the Q1 beat supports stabilizing demand, investors should remain aware of potential risks from weaker biotech funding, which could impact order visibility.
Repligen Corporation (RGEN) Stock Analysis: A Promising 34.85% Upside Potential in the Bioprocessing Sector
Repligen Corporation (RGEN) is highlighted as a compelling investment opportunity in the bioprocessing sector, with analysts projecting a 34.85% upside potential. The company, a key player in medical instruments and bioprocessing technologies, shows strong revenue growth and solid financial health, despite a modest return on equity. Its growth strategy, evidenced by innovative product offerings and strategic partnerships, is supported by strong analyst ratings and positive technical indicators.
RBC Capital Resumes Repligen Corp (RGEN) Stock Coverage. Here’s Its View
RBC Capital has resumed coverage on Repligen Corp (RGEN) with an Outperform rating and a $160 price target, citing the company's diverse growth drivers and strengthening bioprocess market. Analysts anticipate Repligen's stock to rise over 40% based on these factors, predicting a return to mid-teens organic sales growth. The company reported strong Q1 2026 results with a 15% YoY revenue increase and beat analyst expectations for both revenue and adjusted EPS, reinforcing its full-year guidance.
Billionaire Lee Ainslie’s 5 Stocks with Huge Upside Potential
This article highlights Repligen Corp (NASDAQ: RGEN) as one of billionaire Lee Ainslie's top stock picks with significant upside potential. Analysts project a 41.26% upside, and RBC Capital has initiated coverage with an Outperform rating and a $160 price target, citing growth drivers, a strengthening bioprocess market, and strong Q1 2026 results. Repligen's focus is on accelerating profitable growth by making biological drug manufacturing more efficient.
Billionaire Lee Ainslie’s 5 Stocks with Huge Upside Potential
This article highlights Repligen Corp (NASDAQ:RGEN) as one of billionaire Lee Ainslie's top stock picks with significant upside potential. Analysts project the stock to rise over 40%, with RBC Capital resuming coverage with an Outperform rating and a $160 price target, citing growth drivers, a strengthening bioprocess market, and strong Q1 2026 results. Repligen, a bioprocessing company, focuses on accelerating profitable growth through its products that enhance the efficiency of biological drug manufacturing.
Repligen (RGEN) down 3.2% since last earnings report: Can it rebound?
Repligen (RGEN) has seen a 3.2% decline in its stock price since its last earnings report. The article questions whether the company can rebound from this recent downturn.
Repligen Corp (RGEN) Shares Surge 4.0% -- What GF Score of 79 Te
Repligen Corp (RGEN) shares surged 4.0% to $126.55 on June 4, 2026. The stock is considered 27.7% undervalued according to GuruFocus' GF Value™ estimate of $174.94, despite its current P/E (TTM) of 140.6x being significantly above its 5-year median. The company holds a GF Score™ of 79/100, indicating strong growth and financial strength, though recent insider selling of $0.5 million suggests caution for investors.
RGEN - Repligen Corp Stock Price and Quote
This page provides a comprehensive overview of Repligen Corp (RGEN) stock, including its latest financial data, key performance indicators, analyst ratings, and recent news headlines. It details the company's financial metrics such as market cap, P/E ratio, sales, and profit margins, alongside insider trading activities and upcoming events.
Repligen (RGEN) Down 3.2% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) shares have dropped 3.2% since its last earnings report, underperforming the S&P 500. Despite this, the company's Q1 2026 adjusted earnings and revenues surpassed estimates, with strong year-over-year growth across its business franchises. While Repligen lowered its full-year 2026 revenue guidance, it raised its EPS outlook, leading to varied analyst sentiment and a Zacks Rank #3 (Hold).
Repligen (RGEN) Ups Margin Focus After Q1 2026 Beat – Is Its Bioprocessing Pivot Deepening?
Repligen (RGEN) reported a strong Q1 2026 with 15% revenue growth, including 11% organic growth, indicating a renewed focus on margin expansion and portfolio quality after a challenging previous year. The company's robust balance sheet and cash generation offer flexibility for M&A and expansion, particularly into higher-value bioprocessing areas and global markets. This strategic pivot, including the opening of a new Training & Innovation Center, reinforces its long-term investment narrative despite ongoing risks related to customer concentration and volatile market segments.
Total current liabilities of Repligen Corporation – SWB:RGN
This article provides a financial snippet for Repligen Corporation (SWB:RGN), specifically focusing on its total current liabilities. It shows the period, value, and percentage change of these liabilities. The content appears to be a stub from a financial data platform like TradingView, lacking detailed analysis or a full report.
Wolfe Research initiates Repligen stock coverage with outperform rating By Investing.com
Wolfe Research initiated coverage on Repligen Corp. (NASDAQ:RGEN) with an outperform rating and a price target of $145.00, representing 60 times the firm’s 2027 EPS estimate. The firm's analysis supports this valuation if Repligen achieves 15% annual growth and raises its EBIT and EBITDA margins by 2030, despite the stock currently trading at a premium P/E ratio of 135. This initiation follows recent positive momentum for Repligen, including strong Q1 2026 financial results and RBC Capital also resuming coverage with an outperform rating.
Wolfe Research initiates Repligen stock coverage with outperform rating
Wolfe Research has initiated coverage on Repligen Corp. (NASDAQ:RGEN) with an outperform rating and a price target of $145.00, based on 60 times their 2027 EPS estimate. The firm believes this valuation is justified if Repligen achieves 15% annual growth and raises its EBIT and EBITDA margins by 2030, despite current InvestingPro analysis suggesting the stock is overvalued. This comes after Repligen reported strong Q1 2026 financial results, exceeding analyst expectations, and RBC Capital also resumed coverage with an outperform rating.
Repligen Corp. Hits Day High with 8.45% Surge in Stock Price
Repligen Corp. (NASDAQ: RGEN) experienced a significant 8.45% intraday stock surge to USD 126.56, outperforming the S&P 500's modest gain. Despite this short-term boost, the company faces long-term challenges, including a one-year return of -7.65% and underperformance against the S&P 500 over three years, coupled with a low return on equity of 2.32%. However, Repligen maintains a net-debt-free status and strong long-term sales growth of 16.70%, with 100% institutional ownership.
Repligen Jumps 6.2% Amid Sector-Wide Rally
Repligen Corporation's stock surged by 6.2% to $120.24 on Thursday, driven by a sector-wide rally in the medical instruments and supplies industry. This increase, which lifted the company's market capitalization to $6.8 billion, was not due to company-specific news but rather a broader market movement affecting several peers simultaneously. The coordinated gains among multiple companies suggest a shift in investor sentiment or technical buying pressure across the sector.
Is Repligen’s (RGEN) New ESG Report Hinting at a Shift in Its Long-Term Capital Play?
Repligen Corporation recently released its 2025 Corporate Sustainability Report, detailing advancements in renewable energy use, water conservation, and ESG governance. Concurrently, analysts have expressed renewed optimism regarding the bioprocess market and Repligen's growth drivers. This combination is leading investors to consider how sustainability and innovation will influence the company's long-term capital allocation strategies and overall profile.
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation (NASDAQ:RGEN) announced its participation in the William Blair 46th Annual Growth Stock Conference. Olivier Loeillot, President and CEO, will present a company overview on June 3rd at 10:40 a.m. CT, with a live webcast available on Repligen's Investor Relations website. Repligen is a global life sciences company specializing in bioprocessing technologies for biological drug manufacturing.
Hear Repligen's CEO give company overview at June 3 webcast
Repligen (NASDAQ: RGEN), a life sciences company, announced that its President and CEO, Olivier Loeillot, will present a company overview at the William Blair 46th Annual Growth Stock Conference on June 3 at 10:40 a.m. CT. The presentation will be available via live webcast and replay on the company's Investor Relations website. This event follows a series of recent updates including earnings, sustainability reports, and operational expansions.
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation (NASDAQ:RGEN) announced its participation in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and CEO, will present a company overview on June 3rd at 10:40 a.m. CT. A live webcast of the presentation will be available on Repligen’s Investor Relations website and for replay.
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation (NASDAQ:RGEN) announced its participation in the William Blair 46th Annual Growth Stock Conference. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT, with a live webcast available on Repligen's Investor Relations website. The company is a global life sciences company specializing in bioprocessing technologies for manufacturing biological drugs.
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
Repligen Corporation (NASDAQ:RGEN) announced it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and CEO, is scheduled to present a company overview on June 3rd at 10:40 a.m. CT. A live webcast and replay will be available on Repligen's Investor Relations website.
InvestingPro’s Fair Value model predicted Repligen’s 45% decline By Investing.com
InvestingPro's Fair Value model accurately predicted a 45% decline in Repligen Corporation's stock price between February 2024 and May 2026, flagging it as significantly overvalued despite seemingly sound fundamentals. The model's success highlights its ability to identify mispriced stocks by combining various valuation methodologies. This case study demonstrates the importance of systematic valuation analysis in helping investors avoid substantial losses.
Repligen Corp stock (US7607591002): ESG progress and growth focus draw fresh attention
Repligen Corp has released its latest sustainability update, emphasizing ambitious environmental targets such as utilizing 100% renewable electricity for manufacturing and reducing water usage. The company, a specialist in bioprocessing technologies, is also continuing to invest in high-growth bioprocessing technologies. Investors are closely monitoring how the firm's ESG progress and the ongoing demand from biotech customers will influence the stock's long-term trajectory.
Repligen Corp stock (US7607591002): ESG progress and growth focus draw fresh attention
Repligen Corp, a bioprocessing technology specialist, has released a sustainability update highlighting its ESG progress, including increased use of renewable electricity and resource efficiency. The company focuses on providing critical technologies for biologic drug production, such as filtration and chromatography solutions, serving pharmaceutical and biotech firms. Investors are observing how Repligen's ESG initiatives and demand from biotech customers will influence its long-term stock performance within the competitive bioprocessing tools industry.
Repligen Announces Publication of the Company’s 2025 Corporate Sustainability Report
Repligen Corporation has released its 2025 Corporate Sustainability Report, titled "Driving Sustainable Growth Together," detailing its progress across six key impact areas including Products & Packaging, Operations, and Supply Chain. The report aligns with UN Sustainable Development Goals, GRI Standards, SASB Standards, and TCFD. Key highlights include maintaining 100% renewable electricity in US and European manufacturing, completing a Double Materiality Assessment, and strengthening governance oversight for sustainability.
